compound-24

>50x family-selective HPK1 kinase inhibitor

tumor clearance w/ PD-1i (oral 100 mpk BID)

from IRAK4 inhibitor and homology modeling

ACS. Med. Chem. Lett., Feb. 19, 2021

Bristol Myers Squibb, Cambridge, MA

6. The Bristol Myers Squibb (BMS) HPK1 kinase inhibitor, “compound 24” is an oral tool compound intended for cancer immunotherapy, with >50x selectivity against family members including GLK. The…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.